Southlake-based HeartSciences, which closed on a $6.375M IPO in June, applies AI-based technology to an ECG to detect cardiac dysfunction—one of the earliest signs of heart disease. The company says…
Patent continues to strengthen and expand IP portfolio Southlake, Texas, Sept. 20, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused…
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas, September 13,…
Andrew Simpson, HeartSciences Chairman and Chief Executive Officer presents at the H.C. Wainwright 24th Annual Global Investment Conference Webcast (September 12-14, 2022). View the full webcast via the following link: Journey…
Southlake, Texas, Sept. 12, 2022 — Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as…
Southlake, Texas, Sept. 08, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to…
